|
|
||||||||

,
* Department of Laboratory Medicine, Section of Clinical Chemistry, Wallenberg Laboratory, University Hospital Malmö, Lund University, Malmö, Sweden;
Sanquin Research at the CLB and Laboratory for Experimental and Clinical Immunology, Academic Medical Center, Amsterdam, The Netherlands; and
Department of Clinical Chemistry, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
C-reactive protein (CRP) is the major acute phase protein in humans. It has been shown that CRP interacts with factor H, an inhibitor of the alternative pathway of complement, and now we demonstrate binding of CRP to the fluid-phase inhibitor of the classical pathway, C4b-binding protein (C4BP). C4BP bound to directly immobilized recombinant CRP as well as CRP attached to phosphorylcholine. The binding was sensitive to ionic strength and was enhanced in the presence of calcium. C4BP lacking
-chain and protein S, which is a form of C4BP increasing upon inflammation, bound CRP with higher affinity than the C4BP-protein S complex. The binding could not be blocked with mAbs directed against peripheral parts of the
-chains of C4BP while the isolated central core of C4BP obtained by partial proteolytic digestion bound CRP, indicating that the binding site for CRP is localized in the central core of the C4BP molecule. Furthermore, we found complexes in serum from a patient with an elevated CRP level and trace amounts of CRP were also identified in a plasma-derived C4BP preparation. We were also able to detect C4BP-CRP complexes in solution and established that C4BP retains full complement regulatory activity in the presence of CRP. In addition, we found that C4BP can compete with C1q for binding to immobilized CRP and that it inhibits complement activation locally. We hypothesize that CRP limits excessive complement activation on targets via its interactions with both factor H and C4BP.
This article has been cited by other articles:
![]() |
K. E. Happonen, A. P. Sjoberg, M. Morgelin, D. Heinegard, and A. M. Blom Complement Inhibitor C4b-Binding Protein Interacts Directly with Small Glycoproteins of the Extracellular Matrix J. Immunol., February 1, 2009; 182(3): 1518 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Blom, K S Nandakumar, and R Holmdahl C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice Ann Rheum Dis, January 1, 2009; 68(1): 136 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Trouw, A. A. Bengtsson, K. A. Gelderman, B. Dahlback, G. Sturfelt, and A. M. Blom C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack J. Biol. Chem., September 28, 2007; 282(39): 28540 - 28548. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Sjoberg, L. A. Trouw, S. J. Clark, J. Sjolander, D. Heinegard, R. B. Sim, A. J. Day, and A. M. Blom The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells J. Biol. Chem., April 13, 2007; 282(15): 10894 - 10900. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |